Phenotypic features of endometrial tumors in patients with family history of cancer by Buchynska, L.G. et al.
312 Experimental Oncology 39, 312–318, 2017 (December)
PHENOTYPIC FEATURES OF ENDOMETRIAL TUMORS IN PATIENTS 
WITH FAMILY HISTORY OF CANCER
L.G. Buchynska, N.P. Iurchenko*, N.M. Glushchenko, I.P. Nesina
R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine,  
Kyiv 03022, Ukraine
Aim: To determine the peculiarities of expression of a number of proteins-regulators of the cell cycle in endometrial cancer (EC) cells 
in patients with a family history of oncological pathologies. Patients and Methods: 95 EC patients (stage І–ІІ) were included into 
the study. Clinical-genealogical analysis was performed. 54 patients (group I) had healthy relatives, and in families of 41 patients 
(group II) an aggregation of malignant tumors of different genesis (mainly tumors of the gastrointestinal tract and the female repro-
ductive system) was recorded. p53, р21WAF1/CIP1, р16INK4a, and Ki-67 were assessed immunohistochemically in the surgical samples. 
Results: In the majority of patients, both from group I and II, moderately differentiated tumors were observed (in 38.9 and 46.3% 
of cases, respectively), mainly with deep myometrium invasion (64.8 and 58.5% of cases, respectively). In EC patients from group II, 
a significantly higher number of р16INK4a-positive cells (17.7 ± 1.7%; p = 0.001) and lower number of p53-positive (30.9 ± 3.2%; 
p = 0.05) and Ki-67-positive (26.9 ± 2.7%; p = 0.048) cells was observed compared to those in tumors of patients from group I 
(12.0 ± 1.6; 37.7 ± 2.8 and 36.7 ± 3.4%, respectively). Conclusion: Phenotypic features of the EC in the patients with family his-
tory of cancer differ from those in tumors of patients without such aggregation. The biological heterogeneity of EC seems to relate 
to the oncogenealogical history of patients. Also this biological heterogeneity is linked to the molecular features of EC cells, which 
affects cancer aggressiveness and the course of the disease.
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Endometrial cancer (EC) is one of the most com-
mon malignant neoplasms of the reproductive system 
in women, both in Ukraine and in other European coun-
tries. In the structure of oncological pathology of the 
female population, according to the National Cancer 
Register, in 2015 EC occupied the third place [1]. This 
oncopathology occurs predominantly in women over 
50 years old, but according to the results of onco-
epidemiological studies in recent years the number 
of EC patients in young and middle age has increased, 
in particular, 4.0% of cases are diagnosed before the 
age of 40, which definitely affects the demographic sit-
uation. It should be noted that at the time of diagnosis 
of EC metastases are detected in 17.0% of patients [2].
It has been established that the pathogenesis 
of EC, as well as the majority of malignant neoplasms, 
is associated with the influence of hereditary factors 
and exo- or endogenous factors. On the basis of clini-
cal and genealogical analysis of families of EC patients 
from the Kyiv region, the contribution of the genetic 
component to the development of EC is 53.2%, in-
dicating the significant importance of hereditary 
factors in the occurrence of this pathology [3]. The 
incidence of hereditary malignant tumors of the re-
productive system in women, including EC, varies 
from 5.0 to 10.0% [4–6]. To date, there are a number 
of hereditary cancer syndromes, with a systemic pre-
disposition to the emergence of EC. Most often, EC de-
velops in patients with Lynch syndrome (hereditary 
non-polyposis colorectal cancer), the development 
of which is associated with inactivation of genes re-
sponsible for the repair of unpaired DNA bases (MSH2, 
MLH1, MSH3, MSH6, PMS1, PMS2). In addition, this 
oncopatho logy is observed in Lee-Fraumeni syndrome 
(mutation in the TP53 gene), Cowden syndrome (a mu-
tation in the PTEN gene), BRCA-associated breast and 
ovarian cancer syndrome (BRCA gene inactivation), 
and others [4, 7, 8].
Numerous studies have shown that in most cases 
EC is hormone-dependent malignancy associated with 
the chronic effects of estrogen on the background 
of an impaired estrogen-progesterone balance and 
is heterogeneous in terms of molecular genetic char-
acteristics that are.
Hyperestrogenemia is one of the factors that modu-
lates the expression of genes, which leads to violations 
in the regulation of cellular signals and contributes 
to the pathological proliferation of EC cells [9, 10]. 
The latter is associated with the progression of neo-
plasm: determines the rate of growth, malignancy, 
invasive and metastatic potential of neoplasm [11]. 
Impairment of the proliferation in tumor cells is associ-
ated with a functional imbalance of regulatory genes, 
in particular, the oncosuppressor gene ТР53, cyclin-
dependent kinase (CDK) inhibitors р21WAF1/CIP1 and 
CDKN2A/р16INK4a [12]. The products of these genes 
are the key components of the p53/р21WAF1/CIP1 and 
pRb/p16INK4a signaling pathways, inactivation of which 
results in uncontrolled proliferation of tumor cells and 
determines the biology of malignant tumors [13–18]. 
Our previous studies have shown that EC is char-
acterized by high proliferative activity, which is due 
to changes in expression of the cell cycle regulators 
such as p53, р21WAF1/CIP1 and р16INK4a, and is associated 
with the tumor differentiation grade [19].
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According to current views on the pathogenesis 
of tumors of the female reproductive system, genetic 
factors play an important role in shaping the biological 
characteristics of malignant tumors that may deter-
mine prognosis. According to some authors, sporadic 
and hereditary forms of breast and ovarian cancer are 
characterized by certain morphological, clinical and 
functional differences, in particular, the degree of ma-
lignancy, the hormone receptor phenotype, the course 
of the disease, etc. [4, 7, 8]. Despite the achievements 
in the field of oncology, to this time in clinical practice 
insufficient attention is paid to the assessment of the 
role of hereditary factors that determine the biologi-
cal features of malignant neoplasms and the clinical 
polymorphism of the disease. Data on the biological 
features of endometrial tumors occurring in patients 
with a family history of cancer are practically absent 
in the modern literature.
Taking into account the above-mentioned, the aim 
of the study was to determine the expression of the 
cell cycle regulatory proteins in EC of the patients with 
a family history of cancer.
MATERIALS AND METHODS
The work was performed on the surgical samples 
of 95 EC patients in FIGO stages I or II who did not 
receive special treatment before surgery. The patients 
were operated in the research department of oncogy-
necology at the National Cancer Institute of the Ministry 
of Health of Ukraine. An average age of the patients was 
58.3 ± 1.1 years (from 36 to 83 years). Genealogical in-
formation on the burden of a family history of cancer was 
obtained in a direct survey of EC patients. All patients 
were informed and agreed to use their private informa-
tion and operational material for research.
The study of family history of EC patients was car-
ried out with the help of a specially developed clinical 
genealogy card, which included information on the 
diseases of relatives of the I and II relation degree, the 
patient’s living conditions and related diseases. The 
criteria for the distribution of EC patients to the group 
with a burdened family history of oncological pathology 
were: presence in the proband’s family of two or more 
relatives with the I relation degree, or one relative 
of the I relation degree and two of the II degree with 
neoplasms of the female reproductive system and the 
gastrointestinal tract and the earlier age (≤ 50 years) 
of the manifestation of the disease [20]. In addition, 
information was taken into account on the clinical 
course of the disease, the depth of invasion of the tu-
mor in myometrium, the survival rate of patients after 
treatment, which was obtained in the study of disease 
history and outpatient card.
The morphological diagnosis and tumor differentia-
tion grade were determined on preparations stained 
with hematoxylin and eosin according to WHO criteria 
(2014) [21].
To determine the cell counts in the phases of the 
mitotic cycle, a flow cytometry using flow cytometer 
EPICSXL (Becton Coulter, USA). Cell suspension from 
surgical EC samples was prepared by mechanical dis-
aggregation of the tissue using a special device called 
Medimachine (Becton Dickinson, Italy), followed 
by propidium iodide (Sigma-Aldrich, USA) staining.
Immunohistochemical detection of biomarkers was 
performed on parallel deparaffined sections using 
primary monoclonal antibodies against Ki-67 (clone 
MIB-1; Dako, Denmark), p53 (clone DO-7; Dako, 
Denmark), р21WAF1/CIP1 (clone HZ52; Dako, Denmark), 
р16INK4a (clone JC8; Abcam, UK), and PolyVue HRP/
DAB Detection System (Diagnostic BioSystems, USA).
The results of immunohistochemical reaction were 
evaluated by a semi-quantitative method by counting 
the percentage of positively stained cells (labeling 
index — LI). The proliferative potential was deter-
mined by the number of cells expressing the marker 
of proliferation Ki-67 (proliferation index — PI). Ex-
pression of markers was analyzed per 1000 tumor 
cells. The significance of the LI and the PI less than 
the median was considered to be low for the expres-
sion of the corresponding marker, and with the values 
of LI and PI above median — high. It was found that 
median expression of Ki-67 in sporadic EC was 31.4%, 
in the EC of patients with family history of cancer, the 
Ki-67 expression was 29.0%.
The data were processed using the Statistica 
7.0 software package (StatSoft, Inc., USA). The follow-
ing statistical methods were used: standard descriptive, 
nonparametric (Mann — Whitney, χ2-test), correlation 
(Spearman correlation coefficient). p < 0.05 was con-
sidered statistically significant. The analysis of survival 
of EC patients was performed using the Kaplan — Meier 
method.
RESULTS
The analysis of clinical-genealogical data on pedi-
grees of 54 EC patients (Group I) found no aggregation 
of oncological pathology, while in families of 41 pro-
bands (Group II) there was revealed the accumulation 
of malignant tumors of different genesis (Table 1). 
Most often these were the tumors of the gastrointes-
tinal tract and the female reproductive system.
Table 1. Aggregation of malignant neoplasms in proband families —  
patients with EC
Degree  
of relation-
ship
Tumor type, n (%)
EC BC OC CGIT LC
Other 
localiza-
tions
Total
І
(mother, fa-
ther, sister, 
brother, chil-
dren)
10  
(15.4)
9  
(13.8)
3
(4.6)
20
(30.8)
11
(16.9)
12
(18.5)
65
ІІ
(aunt, uncle, 
grandmother, 
grandfather)
9
(17.3)
7
(13.5)
– 23
(44.2)
7
(13.5)
6
(11.5)
52
Total 19
(16.2)
16
(13.6)
3
(2.6)
43
(36.8)
18
(15.4)
18
(15.4)
117
Note: *BC — breast cancer; CGIT — cancer of the gastrointestinal tract 
(colorectal, stomach, esophagus, liver, pancreas, gallbladder); OC — ovar-
ian cancer; LC — lung cancer.
It should be noted that in families of 24 (58.5%) 
EC patients an aggregation of tumors of the colon, 
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stomach, endometrium, and ovary was observed. The 
association of EC, breast cancer and ovarian cancer 
was found in 10 (24.4%) pedigrees, and in 7 (17.1%) 
EC patients was revealed in relatives of the I and II rela-
tion degree [22, 23].
Comparison of the age of manifestation of onco-
logical disease in two groups of patients showed that 
in patients with a family history of cancer, EC occurred 
at a younger age (55.7 ± 1.5%), compared with those 
in patients without aggregation of cancer pathology 
in pedigrees (Table 2).
Table 2. Clinical and morphological characteristics of EC patients  
depending on a family history of cancer
Clinical and morphological 
parameters
Number of EC cases, n (%)
Without aggregation 
of oncological patholo-
gy in families,
N = 54
With aggregation 
of oncological pa-
thology in families,
N = 41
Average age (range), years 63.2 ± 1.4  
(50–76)
55.7 ± 1.5  
(26–59)
Tumor differentiation grade:
G1 high
G2 moderate
G3 low
17 (31.5)
21 (38.9)
16 (29.6)
9 (22.0)
19 (46.3)
13 (31.7)
Invasion depth into myome-
trium:
< ½
> ½
19 (35.2)
35 (64.8)
17 (41.5)
24 (58.5)
Morphologically the endometrial carcinomas with 
varied differentiation grade and the depth of invasion 
were demonstrated in surgical specimens from both 
groups of patients (see Table 2). In patients with ag-
gregation of oncopathology in pedigrees, most of the 
tumors (46.3%) were moderately differentiated with 
an invasion of less than half myometrium (41.5%).
The analysis of the results of the immunohisto-
chemical study of biomarkers in the EC revealed 
a significant variability of the individual parameters 
both by the number of tumor cells expressing tumor 
suppressors and by the proliferative activity (Fig. 1).
In particular, in patients of Group I, the number 
of tumor cells with the expression of p53 varied within 
the range of 5.3–83.0%, р21WAF1/CIP — 1.6–36.6%, 
р16INK4a — 3.0–37.4% and the marker of proliferation 
Ki-67 (2.0–89.7%). In EC of patients from Group II, 
individual variations in the number of tumor cells with 
the expression of these proteins were slightly differ-
ent: p53 (5.1–74.0%), р21WAF1/CIP (2.2–29.0%), р16INK4a 
(7.0–39.8%), Ki-67 (9.3–64.2%).
In EC of patients with aggregation of oncologi-
cal pathology in families there was detected a larger 
number of cells with expression of protein suppressor 
р16INK4a (17.7 ± 1.7%; p = 0.001) and lower numbers 
of cells with expression of p53 (30.9 ± 3.2%; p = 0.05) 
and the marker of Ki-67 proliferating cells (26.9 ± 2.7%; 
p = 0.048), compared to those in tumors of patients 
without aggregation of oncological pathology in fami-
lies (12.0 ± 1.6; 37.7 ± 2.8, 36.7 ± 3.4%, respectively) 
(Fig. 2). Tumors of Groups I and II of EC patients were 
Fig. 1. Immunohistochemical expression of p21WAF1/CIP1 (a), р16INK4a (b), p53 (c), Ki-67 (d) in the endometrial adenocarcinoma. 
Counterstained by Mayer hematoxylin. × 400
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characterized by almost the same number of cells with 
expression of CDK inhibitor р21WAF1/CIP.
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Fig. 2. Expression of biomarkers in tumors of EC patients de-
pending on a family history of cancer
It was determined that in the group of patients with 
sporadic tumors prevailed high-proliferating (59.0%) 
tumors, while in the patients with a family history of can-
cer, the number of such tumors was 43.9% (p < 0.05). 
A correlation relationship was established (r = 0.6; 
p = 0.01) between the indexes of expression of the 
Ki-67 and the p53. That is, the proliferation of sporadic 
EC cells significantly increased with high expression 
of p53. These data are confirmed by the results of cy-
tofluorometric studies, which showed a significantly 
(p < 0.05) higher number of cells (78.9 ±  1.7%) in G0/
G1 and lower in S + G2 + M (21.1 ± 0. 5%) phases of the 
cell cycle in carcinomas of patients with an burdened 
family history of cancer compared to the patients with 
sporadic EC (69.0 ± 1.2 and 31.0 ± 0.7%, respectively).
Thus, EC of patients with a family history of on-
cological pathology is characterized by a lower ex-
pression of the Ki-67 proliferation marker and tumor 
suppressor protein p53 with the simultaneous growth 
of the expression of the CDK inhibitor р16INK4a.
Analysis of the expression of biomarkers depend-
ing on differentiation grade of the EC showed that the 
number of tumor cells with the expression of proteins 
Ki-67 and p53 in both groups of patients increased 
in the direction from high to moderate and low-dif-
ferentiated tumors. However, the rates of Ki-67 and 
p53 were significantly lower in G1 and G3 tumors of pa-
tients with family history of cancer (Table 3).
Table 3. Expression of biomarkers in EC of varying differentiation grade 
in patients without aggregation (Group I) and aggregation of tumor patho-
logy in pedigrees (Group II)
Biomarker Groups 
of patients
Cell number, % (М ± m)
G1 G2 G3
p53 І 33.2 ± 5.0 31.1 ± 4.5 53.9 ± 5.5*,**
ІІ 18.5 ± 5.4# 27.1 ± 3.8 44.9 ± 5.1*,**
p21WAF1/CIP1 І 7.3 ± 1.1 16.7 ± 4.3*,** 11.4 ± 1.7
ІІ 18.1 ± 2.2# 11.4 ± 1.3 9.2 ± 3.0*
p16INK4a І 17.2 ± 2.8 11.1 ± 1.6 7.2 ± 0.9*
ІІ 12.4 ± 1.3 16.5 ± 1.4# 20.3 ± 3.2*,#
Ki-67 І 24.9 ± 2.4 31.6 ± 4.3 52.9 ± 4.6*,**
ІІ 12.9 ± 2.3# 23.1 ± 2.5 42.1 ± 3.3*,**,#
Note: *p < 0.05 compared with G1 tumors; **p < 0.05 compared with G2 tu-
mors; ***p < 0.05 compared with G1 tumors; #p < 0.05 compared with Group II.
It should be noted that the change in the expres-
sion of the proteins р16INK4a та р21WAF1/CIP1 in EC, 
depending on differentiation grades in patients with 
burdened and non-burdened family history of cancer, 
was divergent. In tumors of patients with EC without 
aggregation of oncological pathology in pedigrees, 
along with the decrease of differentiation grade, 
there was observed a decrease in the number of cells 
with expression of protein р16INK4a. At the same time, 
in the tumors of patients with a burdened family his-
tory of cancer, the number of cells expressing р16INK4a 
protein was significantly (p = 0.03) higher in moder-
ately and low-differentiated carcinomas compared 
with EC in Group I patients. The higher number 
of cells with expression of р21WAF1/CIP1 was detected 
in G2 (16.7 ± 4.3) and G3 tumors compared to G1 tumors 
in patients with non-burdened family history of cancer 
(p < 0.05).
In carcinomas of patients with EC with a family his-
tory of cancer, a larger number of cells with expression 
of р21WAF1/CIP1 protein was observed in highly differentiat-
ed tumors, while with reduced differentiation grade the 
number of such cells significantly (p < 0.05) decreased, 
reaching the minimum values in low-differentiated 
neoplasms compared with those in tumors of patients 
without aggregation of oncopathology in family history.
It is known that one of the indicators of progres-
sion of malignant neoplasms is the depth of its inva-
sion in adjacent tissues. Comparison of the expres-
sion of biomarkers in EC with the depth of invasion 
in myometrium showed that tumors with a deep (> ½) 
invasion of the patients from Groups I and II had a sig-
nificantly higher number of cells with expression of the 
p53 protein and Ki-67 proliferation marker compared 
to carcinomas without deep (< ½) invasion (Table 4).
Table 4. Expression of biomarkers in EC depending on the depth of tumor 
invasion in myometrium and the burden of family history of cancer
Biomarkers
Family history of EC patients
Without aggregation 
of oncological pathology
With a family history 
of cancer
The depth of invasion of the tumor in myometrium
< ½ > ½ < ½ > ½
Expression of markers, % (М ± m)
p53 36.8 ± 3.1 41.5 ± 4.1 22.8 ± 3.0# 36.9 ± 3.5
p21WAF1/CIP1 9.4 ± 1.7 14.5 ± 2.1 14.3 ± 1.7# 10.4 ± 0.2
p16INK4a 15.9 ± 2.4 9.6 ± 1.4* 14.6 ± 1.4 18.8 ± 0.5**,#
Ki-67 23.5 ± 3.4 48.1 ± 3.7* 18.9 ± 2.4 32.5 ± 2.3**,#
Note: *p < 0.05 compared with tumors with invasion < ½ myometrium in pa-
tients without aggregation of oncological pathology in family; **p < 0.05 com-
pared with in tumors with invasions < ½ of myometrium in patients with a fam-
ily history of cancer; #p < 0.05 compared with tumors in patients without ag-
gregation of oncological pathology in family.
Instead, in tumors that invaded less than ½ of myo-
metrium in patients with EC from Group I, expression 
levels of p53 and Ki-67 were higher compared to those 
of patients from Group II. It should be noted that the 
change in expression of the proteins р16INK4a and 
р21WAF1/CIP1 in EC with different depth of invasion of both 
groups was similar to the change in the expression 
of these proteins, depending on differentiation grade 
in these groups. Namely, in tumors with an invasion 
> ½ into myometrium, in patients with a non-burdened 
family history of cancer, the higher number of cells 
with the expression of p21WAF1/CIP1 and lower number 
with р16INK4a expression were observed, compared 
with those in patients with a family history of cancer.
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In the study of life expectancy in patients with EC, 
depending on the burden of a family history of cancer, 
it was found that the overall 5-year survival rate in pa-
tients with EC from families without aggregation of on-
cological pathology was 78.0% and was significantly 
lower than in patients with a family history of cancer 
(92.0%) (Fig. 3).
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Fig. 3. Overall 5-year survival rate of EC patients depending 
on a family history of cancer (Kaplan — Meyer, Log-Rank Test, 
p = 0.04)
So, the research has shown that in both groups 
of patients along with the progression of cancer, i.e. 
the decrease of differentiation grade and deep inva-
sion of the tumor in myometrium, the expression of the 
Ki-67 and the p53 progressively increased, but the 
expression of these markers was significantly more 
pronounced in sporadic ECs. Instead, the expression 
of CDK inhibitors р16INK4a and p21WAF1/CIP1 was differ-
ently directed, namely, in the tumors of EC patients 
with a family history of cancer, there was observed 
increased expression of р16INK4a and decreased ex-
pression of p21WAF1/CIP1 in low-differentiated and deeply 
invasive tumors compared to moderately and highly 
differentiated tumors with invasion ≤ ½ in myometrium. 
The phenotypic features of tumors of patients without 
aggregation of oncological pathology in pedigrees 
and from families with a family history of cancer are 
associated with the overall 5-year survival rate of these 
patients.
DISCUSSION
Numerous studies have shown that EC course 
is characterized by significant variability, which 
is determined by the spectrum of genetic disorders, 
in particular, suppressor genes whose protein pro-
ducts are involved in various signaling pathways for cell 
proliferation control, in particular p53, p21WAF1/CIP1 and 
р16INK4a [24, 25].
One of the risk factors for the development of the 
tumor process, including EC, is a burdened fam-
ily history of cancer since it is genetic changes that 
determine the biology of the tumor modulating the 
prognosis of the disease course [4].
In our study, the differences in the clinical course 
of the disease in patients without aggregation of on-
cological pathology in pedigrees and family history 
of cancer have been established. In particular, signifi-
cantly higher overall 5-year survival (92.0%) was ob-
served in patients with EC with a family history of can-
cer, compared with this in patients without aggregation 
of oncological pathology in the pedigree (78.0%). 
A similar view is expressed by other researchers, who 
noticed a more favorable course of the disease in pa-
tients with hereditary EC, compared to patients with 
sporadic EC [23].
Detected differences in the life expectancy 
of patients from Groups І and ІІ were associated with 
certain molecular-biological characteristics of their 
tumors. Thus, in tumors of patients with a burdened 
family history of cancer, there was a significantly lower 
expression of the p53 protein and the marker of pro-
liferating cells Ki-67 and a higher level of р16INK4a than 
in EC of patients without aggregation of oncological 
pathology in families. Along with this, tumors of the 
studied groups of patients revealed discrepancies 
in the expression of CDK inhibitors p21WAF1/CIP1 and 
р16INK4a. In patients with a burden family history of can-
cer, there was found a higher number of cells with the 
expression of р16INK4a and lower of p21WAF1/CIP1 in low-
differentiated carcinomas and deep invasion of myo-
metrium compared with tumors with high differentia-
tion grade and with invasion < ½. Detected phenotypic 
features of tumors of patients with a burdened cancer 
history may be due to a specific spectrum of genetic 
disorders that occur in various signaling pathways 
controlling endometrial cell proliferation, including cell 
cycle p53, p21WAF1/CIP1, and р16INK4a.
Possibly, the lower proliferative activity in EC of pa-
tients with a burdened family history of cancer is due 
to the effect of suppressor protein p16INK4a, which in-
hibits the CDK4/6 binding to cyclin D1, resulting in pRb 
remaining in a hypophosphorylated state in a complex 
with E2F and thus blocking G1/S checkpoint. The latter 
leads to the accumulation of cells in the G0/G1 phase 
of the cell cycle, which we have established during 
a cytometric examination of the distribution of en-
dometrial tumor cells by the phases of the mitotic 
cycle. The results of the study showed a significant 
(p < 0.05) increase in the number of tumor cells in the 
G0/G1 phase, in patients with a family history of cancer 
compared with sporadic EC.
Taking into account the function of the p16 pro-
tein in the cell cycle, it is possible that its increase 
in G3 tumors may be the result of a feedback mecha-
nism in response to the increased proliferative activity 
of tumor cells [26].
According to the literature, in the majority of ma-
lignant tumors of different genesis, there are genetic 
disorders of the gene TP53 [27]. In EC, the aberrant 
expression of p53 is determined by the absence of ex-
pression of its protein product, or its overexpression 
(over 50.0% of tumor cells with p53 expression). In this 
case, EC with aberrant expression of p53 are charac-
terized by a high degree of malignancy, and the pa-
tients with such tumors showed an unfavorable course 
of the disease [28–30]. In our study, it was found that 
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in patients with a burdened family history of cancer, the 
number of tumors with the expression of p53 > 50.0% 
was significantly lower (χ2 = 3.99; p = 0.04), compared 
to the tumors of the patients without aggregation of tu-
mor pathology in pedigree (37.0%).
A small number of tumor cells with p21WAF1/CIP1 pro-
tein expression in low-differentiated tumors of EC pa-
tients with a family history of cancer may result from the 
aberrant functioning of the p53 protein that is unable 
to activate p21WAF1/CIP1, or activation of p21WAF1/CIP1 is pro-
vided by the p53-independent mechanism.
In contrary, in sporadic tumors, the decrease in the 
expression of p16INK4a leads to the activation of a com-
plex of CDK4/6 and cyclin D1, resulting in the phos-
phorylation of Rb and the release of E2F, which acti-
vates the transcription of genes that activate the cel-
lular cycle of S phase, and the Ki-67 increase [31]. The 
reason for the decrease in the expression of p16INK4a 
in EC cells of patients without aggregation of tumor 
pathology in families may be both the methylation 
of the promoter of the CDKN2A/p16INK4A gene and 
the homozygous deletion of 1 exon of this gene [32]. 
It has been shown that the expression of the p16INK4a 
protein is inversely correlated with differentiation grade 
of tumor cells in most endometrioid carcinomas [33], 
and in sporadic EC p16INK4A inactivation is more often 
observed, especially in cases with a more aggressive 
course of the disease [23, 34]. These data are in agree-
ment with the results of our study, which found that 
tumors in patients with EC without a burdened family 
history of cancer differed by a smaller number of cells 
with expression of p16INK4a protein in direct correlation 
with survival rates compared to patients with a family 
history of cancer.
It could not be excluded that high proliferative activi-
ty in Group I of patients is associated with disturbances 
in the signal pathway р53 → p21WAF1/CIP1 ˧ CDK4,6 and 
cyclin D, CDK2 and cyclin A, E. The parallel increase 
in the number of p53 and Ki-67-positive tumor cells 
revealed by us (as confirmed by correlation analysis) 
indicates accumulation of mainly functionally aberrant 
p53 protein in tumors of patients without an aggre-
gated family history of oncological pathology.
The identified alterations in cell proliferation in the 
investigated EC may be associated not only with the 
TP53 gene disturbance but also with the inactiva-
tion of one of the regulators of its expression, the 
MDM2 protein [35, 36]. According to our previous 
studies, with a decrease in EC differentiation grade, 
an increase in the expression ratio of p53/MDM2 is ob-
served, which is due to a drastic decrease in the con-
tent of the MDM2 protein. Along with this, the number 
of tumors with no MDM2 expression increases [37].
According to the literature, a number of solid tu-
mors possess a high expression of p21WAF1/CIP1, while 
retaining the ability to exhibit high proliferative acti-
vity. According to the authors, such tumors may have 
specific phosphorylated forms of p21WAF1/CIP1 (T57, 
T145, S146 or S130) that have lost their inhibitory 
functions [38–40]. That is, the simultaneous growth 
of the expression of p21WAF1/CIP1 and Ki-67 proteins 
in low-differentiated EC of patients without aggrega-
tion of oncological pathology in pedigrees compared 
with their expression in high and moderately differen-
tiated tumors may indicate a lack of inhibitory effect 
of p21WAF1/CIP1 protein on proliferation in tumor cells.
Summing up the results of our study we can con-
clude that a more favorable prognosis of patients with 
EC with aggregation of tumor pathology in pedigrees 
is associated with certain phenotypic peculiarities 
of their tumors, which predetermine a lower degree 
of malignancy of these tumors, compared with patients 
with sporadic EC.
Another mechanism that can explain the more 
favorable prognosis of the disease is the presence 
of microsatellite instability in the tumors of such 
patients, which correlates with a large number of im-
munocompetent cells in the tumor microenvironment, 
in particular, intratumoral lymphocytes, which enhance 
the immune response [41].
Therefore, the biological heterogeneity of the 
EC associated with the hereditary factors is deter-
mined, which modulates molecular-biological features 
of the tumor, and influences the EC aggressiveness 
and the course of the disease.
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